The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Plus Therapeutics Secures AMA PLA Code for CNSide Test to Drive Reimbursement and Growth

Key Facts

1Plus Therapeutics appointed Dr. Randy H. Goodman as VP of Value Strategy & HEOR.

2Goodman will focus on supporting CNSide adoption and the commercialization strategy for REYOBIQ.

Plus Therapeutics (PSTV) has secured a Proprietary Laboratory Analyses (PLA) code from the American Medical Association (AMA) for its CNSide CSF tumor cell enumeration test. This milestone follows the recent appointment of Dr. Randy Goodman as VP of Value Strategy and HEOR to lead the company's commercial expansion. The new dedicated billing code is expected to streamline payer reimbursement processes and facilitate broader clinical adoption across the United States. By securing this code, the company strengthens its position in navigating value-based pricing and health policy for its lead assets, including REYOBIQ. This development marks a critical step in the company's transition toward full-scale commercialization. Analysts suggest that standardized reimbursement will be a key driver for the firm's long-term commercial viability and market penetration.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include the acquisition of a specific AMA PLA billing code, a critical milestone for standardized reimbursement and commercial scaling.